Beyond trastuzumab: Small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer

Oncologist

Volumn 14, Issue 11, 2009, Pages 1061-1069

  Roy, Vivek ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Breast cancer; HER 2; Lapatinib; Trastuzumab; Tyrosine kinase inhibitors

Indexed keywords

4 [1 (3 FLUOROBENZYL) 5 INDAZOLYLAMINO] 5 METHYLPYRROLO[2,1 F][1,2,4]TRIAZINE 6 CARBAMIC ACID 3 MORPHOLINOMETHYL ESTER; ANTHRACYCLINE; CANERTINIB; CAPECITABINE; CP 724714; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; N [4 (3 CHLORO 4 FLUOROANILINO) 7 (TETRAHYDRO 3 FURYLOXY) 6 QUINAZOLINYL] 4 DIMETHYLAMINO 2 BUTENAMIDE; NERATINIB; PACLITAXEL; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; TAK 285; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; ANTIGEN BINDING; ASTHENIA; BINDING KINETICS; BLOOD BRAIN BARRIER; BREAST CANCER; DEHYDRATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HEART DISEASE; HUMAN; HYPERBILIRUBINEMIA; LUNG EMBOLISM; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN KINASE INHIBITORS; RECEPTOR, ERBB-2;

EID: 75449089516     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0142     Document Type: Review

References (66)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244: 707-712.
3. Perez EA, Romond EH, Suman VJ et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract 512]. J Clin Oncol 2007;25(18 suppl):6s.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353: 1673-1684.
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
6. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17: 2639-2648.
7. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719 -726.
8. Burstein HJ, Kuter I, Campos SM et al. Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2001;19:2722-2730.
9. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800 -1808.
10. O'Shaughnessy JA, Vukelja S, Marsland T et al. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 2004;5:142-147.
11. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96:739 -749.
12. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
13. Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12(suppl 1):S35-S41.
14. Sliwkowski MX, Lofgren JA, Lewis GD et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(suppl 12):60 -70.
15. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172.
16. Molina MA, Codony-Servat J, Albanell J et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61:4744-4749.
17. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
18. Pietras RJ, Fendly BM, Chazin VR et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829 -1838.
19. HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 2006;12:424-431.
20. Nagy P, Friedländer E, Tanner M et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 2005;65:473-482.
21. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108:334 -341.
22. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117-127.
23. Nahta R, Takahashi T, Ueno NT et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 2004; 64:3981-3986.
24. Gundla R, Kazemi R, Sanam R et al. Discovery of novel small-molecule inhibitors of human epidermal growth factor receptor-2: Combined ligand and target-based approach. J Med Chem 2008;51:3367-3377.
25. Nahta R, Yuan LX, Du Y et al. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667- 674.
26. Sartor CI, Zhou H, Kozlowska E et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 2001;21:4265- 4275.
27. Gril B, Palmieri D, Bronder JL et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst 2008;100: 1092-1103.
28. Lin NU, Carey LA, Liu MC et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2008;26:1993-1999.
29. Wang SE, Narasanna A, Perez-Torres M et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10:25-38.
30. Gomez H, Chavez M, Doval D et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer [abstract 3046]. J Clin Oncol 2005;23:(16 suppl):203s.
31. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743.
32. +) metastatic breast cancer: Quality-of-life assessment. Breast Cancer Res Treat 2009;117:577-589.
33. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-543.
34. +) metastatic breast cancer (MBC): First results from the EGF30008 Trial. Cancer Res 2009;69(2 suppl). [Abstract 46 presented at the 31st Annual Cancer Therapy&Research Center-American Association for Cancer Research San Antonio Breast Cancer Symposium, December 12, 2008.]
35. Zembryki D, Gomez H, Koehler M et al. Cardiac safety of the lapatinib/letrozole combination as first-line therapy in patients (pts) with metastatic breast cancer (MBC) [abstract 1095]. J Clin Oncol 2009;27(15 suppl).
36. Trudeau ME, Johnston S, Kaufman B et al. Lapatinib (Tykerb) monotherapy in patients with recurrent inflammatory breast cancer: Clinical activity and biological predictors of response [abstract 1400a]. Ann Oncol 2006;17(suppl 9).
37. Cristofanilli M, Boussen H, Baselga J et al. A phase II combination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer (IBC) [abstract 1]. Breast Cancer Res Treat 2006;100(suppl 1).
38. + breast cancer [abstract 503]. J Clin Oncol 2006; 24(18 suppl).
39. Austin CD, De Mazière AM, Pisacane PI et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268 -5282.
40. Scaltriti M, Verma C, Guzman M et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 2009;28:803- 814.
41. + metastatic breast cancer progressing on trastuzumab therapy [abstract 1015]. J Clin Oncol 2008;26(15 suppl).
42. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22:322-329.
43. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-344.
44. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908 -916.
45. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: Pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83:679-686.
46. + breast cancer. Abstract 37 presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-14, 2008.
47. Chow L, Jiang Z, Epstein R et al. Safety and efficacy of neratinib (HKI-272) in combination with paclitaxel in patients with solid tumors [abstract 3557]. J Clin Oncol 2009;27(15 suppl).
48. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study [:abstract 1004]. J Clin Oncol 2009;27(15 suppl).
49. Baselga J, Hammond LA. HER-targeted tyrosine-kinase inhibitors. Oncology 2002;63(suppl 1):6 -16.
50. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001;28(suppl 16):80-85.
51. Nemunaitis J, Eiseman I, Cunningham C et al. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846 -3853.
52. Rixe O, Franco SX, Yardley DA et al.Arandomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol 2009;64:1139 -1148.
53. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001;61:5407-5414.
54. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324: 1-8.
55. Li M, Ye C, Feng C et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-antisense therapy. Clin Cancer Res 2002;8:3570 -3578.
56. Holden SN, Eckhardt SG, Basser R et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16:1391-1397.
57. Miller KD, Trigo JM, Wheeler C et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11:3369 -3376.
58. Boer K, Lang I, Lombart-Cussac A et al. Vandetanib with docetaxel as second line treatment for advanced breast cancer: A double-blind, placebo controlled, randomized phase II study. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 13-16, 2007.
59. ZACtima FASlodex Trial (ZACFAST): A Randomised, Double-Blind, Parallel-Group, Multicentre, Phase II Study to Evaluate the Safety and Pharmacological Activity of the Combination of Vandetanib (100 or 300 MG/ Daily or Placebo) With Fulvestrant (Loading Dose), In Postmenopausal Advanced Breast Cancer Patients. Available at http://www.clinicaltrials.gov/ct2/show/ NCT00752986, accessed May 17, 2009.
60. Taylor SK, Chia S, Dent S et al.Aphase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. J Clin Oncol 2009;27(suppl 15):1133.
61. Slamon D, Gomez HL, Kabbinavar FF et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2- positive advanced or metastatic breast cancer [abstract 1016]. J Clin Oncol 2008;26(15 suppl).
62. Hayashi A, Tamura T, Yusa T et al. A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing breast cancer. Abstract 3143 presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 10-14, 2008.
63. Hickish T, Wheatley D, Lin N et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab [abstract 1023]. J Clin Oncol 2009;27(15 suppl).
64. Awada AH, Dumez H, Wolter P et al. A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors [abstract 3556]. J Clin Oncol 2009;27(15 suppl).
65. Wong TW, Lee FY, Yu C et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res 2006;12:6186-6193.
66. Munster PN, Britten CD, MitaMet al. First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors. Clin Cancer Res 2007;13:1238 -1245.